Consistent with this, previous studies have shown that although there is modest single agent activity of PI3K-AKT or MEK-ERK1/2 inhibitor, neither exhibits a meaningful in vivo tumor regression nor improves survival in PDAC [40-42]. This evidence concerns the gene AKT1 and neoplasm.